Source:http://linkedlifedata.com/resource/pubmed/id/11857534
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2002-2-21
|
pubmed:abstractText |
Human papillomavirus (HPV) DNA testing can be used to identify women at risk of the development of cervical cancer. The cost-effectiveness of HPV screening is dependent on the type-specific HPV prevalence in the general population. The present study describes the prevalence and spectrum of high-risk HPV types found in a large real-life population-based HPV screening trial undertaken entirely within the cervical screening program offered to middle-aged Swedish women. Cervical brush samples from 6,123 women aged 32-38 years were analyzed using a general HPV primer (GP5+/6+) polymerase chain reaction-enzyme immunoassay (PCR-EIA) combined with reverse dot-blot hybridization for confirmation and HPV typing by a single assay. In this study, 6.8% (95% CI 6.2-7.5) (417/6,123) were confirmed as high-risk HPV positive. Infections with 13 different high-risk HPV types were detected, of which HPV 16 was the most prevalent type (2.1%; 128/6,123), followed by HPV 31 (1.1%; 67/6,123). Any one of the HPV types 18, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 66 was detected in 3.6% (223/6,123) of the women. Infection with two, three, and five types simultaneously was identified in 32, 5, and 1 women, respectively. The combination of PCR-EIA as a screening test and reverse dot-blot hybridization as a confirmatory test, was found to be readily applicable to a real-life population-based cervical screening. The type-specific HPV prevalence found support in previous modeling studies suggesting that HPV screening may be a favorable cervical screening strategy.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0146-6615
|
pubmed:author |
pubmed-author:AntonssonAnnikaA,
pubmed-author:DillnerJoakimJ,
pubmed-author:EdlundKarinK,
pubmed-author:ForslundOlaO,
pubmed-author:HanssonBengt-GöranBG,
pubmed-author:JohanssonBoB,
pubmed-author:MeijerChris J L MCJ,
pubmed-author:RydWalterW,
pubmed-author:RylanderEvaE,
pubmed-author:StrandAndersA,
pubmed-author:WadellGöranG,
pubmed-author:van den BruleAdrian J CAJ
|
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:volume |
66
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
535-41
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11857534-Adult,
pubmed-meshheading:11857534-Cervix Uteri,
pubmed-meshheading:11857534-Female,
pubmed-meshheading:11857534-Humans,
pubmed-meshheading:11857534-Immunoblotting,
pubmed-meshheading:11857534-Immunoenzyme Techniques,
pubmed-meshheading:11857534-Mass Screening,
pubmed-meshheading:11857534-Papillomaviridae,
pubmed-meshheading:11857534-Papillomavirus Infections,
pubmed-meshheading:11857534-Polymerase Chain Reaction,
pubmed-meshheading:11857534-Population Surveillance,
pubmed-meshheading:11857534-Prevalence,
pubmed-meshheading:11857534-Sweden,
pubmed-meshheading:11857534-Tumor Virus Infections
|
pubmed:year |
2002
|
pubmed:articleTitle |
Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women.
|
pubmed:affiliation |
Department of Medical Microbiology, Lund University, University Hospital, Malmö, Sweden. ola.forslund@mikrobiol.mas.lu.se
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|